Streetbeat News

Revenues

ZBH

Zimmer Biomet Holdings (NYSE:ZBH) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for ZBH has increased by 5.57% to $134.29. Analyst actions include rating adjustments and price target changes, reflecting dynamic market conditions and company performance. Zimmer Biomet, a leader in orthopedic reconstructive implants, has shown a revenue growth of 6.3% but lags behind industry peers. Its net margin outperforms industry averages, yet its ROE is below benchmarks.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

SPY

Fed Chair Powell highlighted the economy's solid growth and a strong but rebalancing labor market. He noted that inflation is on a path to decrease to 2%, albeit on a sometimes bumpy trajectory. The rebalancing of the labor market is evidenced by data on quits, job openings, and surveys from employers and workers, alongside a continued gradual decline in wage growth.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 4:12 pm

DAR

Darling Ingredients (NYSE:DAR) has received mixed evaluations from 8 analysts over the past three months, with a shift towards a more indifferent stance in the last 30 days. The average 12-month price target for DAR has been adjusted to $65.62, down from $74.00, reflecting a decrease in analyst optimism. The company's financial performance shows a revenue decline of -8.71% over the last quarter, a strong net margin of 5.24%, and an ROE of 1.88%, but it carries a high debt-to-equity ratio of 1.01, indicating potential financial challenges.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 4:01 pm

MEG

Montrose Environmental Gr (NYSE:MEG) received mixed analyst ratings with an updated average 12-month price target of $46.57, reflecting an 11.76% increase from the previous target. Analysts from firms like Stifel and JP Morgan have raised their price targets, indicating a positive outlook on the company's performance. Montrose Environmental Gr's recent financials show an 18.8% revenue growth and a net margin of -3.34%, with a below-average market capitalization and debt-to-equity ratio, suggesting a smaller scale but efficient operation compared to industry peers.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 4:01 pm

PAYX

Recent analyst ratings for Paychex (NASDAQ:PAYX) show a consensus of indifference with all 4 analysts giving a neutral rating over the last three months. The average 12-month price target for PAYX has been adjusted to $121.0, reflecting a slight increase from the previous $120.00. Paychex, a leading provider of payroll and human capital management solutions, has shown strong financial performance with a revenue growth rate of 5.68%, a net margin of 31.22%, and an ROE of 11.04%. The company's market capitalization and financial metrics indicate a robust financial health and investor confidence.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 4:00 pm

ABT

Analyst ratings for Abbott Laboratories (NYSE:ABT) show a positive trend with 7 analysts offering diverse opinions over the last three months. The average 12-month price target has been raised to $129.43 from $125.00, indicating a 3.54% increase. Recent actions by analysts include ratings from 'Buy' to 'Outperform' with price target adjustments reflecting optimism about the company's performance. Abbott's financial metrics such as revenue growth, net margin, ROE, ROA, and debt management are highlighted, showcasing its strong market position and financial health.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 4:00 pm

TLRY

A new study by Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY), shows older patients increasingly choosing cannabis for treating chronic pain, arthritis, anxiety, and insomnia. The study, derived from the Canadian Cannabis Patient Survey 2021, included 2,697 patients with a mean age of 54.3. It highlights a significant reduction in the use of prescription opioids among these patients. This research, along with other studies, indicates a growing trend of cannabis consumption among seniors for medical purposes.

Portfolio Pulse from Jelena Martinovic

April 03, 2024 | 3:12 pm

BG

Analyst ratings for Bunge Global (NYSE:BG) show diverse outlooks, with recent evaluations indicating a shift towards a more cautious stance. The average 12-month price target has been adjusted to $119.78, marking a 10.61% decrease from the previous target of $134.00. Despite this, the majority of analysts remain bullish. Bunge Global's financial overview reveals a strong market presence but a negative revenue trend, with a -15.11% growth over 3 months. However, its net margin, ROE, and ROA outperform industry averages, indicating efficient cost management and financial health.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:01 pm

ADM

In the past three months, 13 analysts have updated their ratings on Archer-Daniels Midland (NYSE:ADM), with the majority maintaining a neutral stance. The 12-month price targets show a significant decrease, with the current average at $62.62, down from $87.09. Analysts have adjusted their ratings and price targets in response to market dynamics and ADM's performance, including a notable -11.42% decline in revenue growth and strong financial indicators such as net margin and ROE. ADM is a major agricultural commodity processor and grain merchandiser, facing challenges but also demonstrating financial health through efficient cost management and asset utilization.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:01 pm

SHC

Sotera Health (NASDAQ:SHC) has received mixed analyst ratings over the past three months, with a total of 6 ratings including 2 bullish and 4 somewhat bullish. The 12-month price targets show an average of $17.92, indicating a 10.28% increase from the previous average of $16.25. Analysts from Citigroup, Jefferies, RBC Capital, and Barclays have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Sotera Health, specializing in sterilization and analytical lab testing, has shown notable financial performance with a revenue growth rate of 23.31%, a net margin of 12.49%, and an ROE of 9.44%, despite a high debt-to-equity ratio of 5.24.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 3:01 pm